Identifying these factors before surgery helps target prevention, such as who needs gentler techniques, closer follow-up, or pre-emptive therapies
Consultings Executive Insights will explore how payers should strategize their approach to glucagon-like peptide-1 agonists (GLP-1s) as they weigh rising consumer demand and increasing pharma supply with recognition of longer-term return on investment (ROI) opportunity
Ulta Lab Tests offers convenient access to GLP-1 monitoring panels and individual biomarkers
Many patients continue treatment to maintain results, with periodic reviews to adjust dosing and confirm the plan still fits
Summary: GLP-1 receptor agonists may reduce alcohol consumption in some individuals, but they are not approved for treating alcohol use disorder and evidence remains preliminary
Real-world data from weight-loss clinics show that 1525% of patients on sustained GLP-1 therapy develop deficiencies in vitamin B12, iron, or calcium within 612 months if intake and absorption are not actively managed